Clinical trials: CMS
Myasthenic Syndromes, Congenital
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain…
- Trial name
- NCT02562066
- Testing
- amifampridine phosphate
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.